Select your localized edition:

Close ×

More Ways to Connect

Discover one of our 28 local entrepreneurial communities »

Be the first to know as we launch in new countries and markets around the globe.

Interested in bringing MIT Technology Review to your local market?

MIT Technology ReviewMIT Technology Review - logo


Unsupported browser: Your browser does not meet modern web standards. See how it scores »

{ action.text }

A startup based in Cambridge, MA, is commercializing a new kind of rapid diagnostic technology that relies on magnetic nanoparticles and a technique similar to magnetic resonance imaging (MRI). The nanoparticles can be designed to signal the presence of specific viruses and bacteria, particular strands of DNA and proteins including those found on cancer cells, and other molecules such as glucose. The technique can use blood, spit, or any other samples with no preparation. The researchers hope the tool will help doctors identify treatments faster and allow for better monitoring of cancer treatments.

The company, T2 Biosystems, expects to begin marketing diagnostics for infectious diseases in two years, and it’s developing implantable sensors and handheld readers for monitoring diseases such as diabetes and cancer. Prominent researchers from MIT, Harvard, and Massachusetts General Hospital founded the company. Tyler Jacks, director of the MIT Center for Cancer Research and a cofounder of T2, says that the company is developing “more rapid, accurate, portable, and cheaper diagnostics.”

The new diagnostic is based on iron-oxide nanoparticles that generate a strong magnetic signal when exposed to a magnetic field. Each nanoparticle resembles a spiky ball and is coated with molecules like antibodies or single strands of DNA that bind to a specific target. The researchers can design nanoparticles to target just about any molecule. In the absence of the target, the nanoparticles float freely in solution. When the nanoparticles are put in a solution containing the target molecule, they aggregate, each nanoparticle binding to multiple target molecules and creating tangled clumps. The nanoparticles make a different kind of magnetic signal when clumped. This signal can be read in an MRI machine or in a relaxometer, a desktop-sized device.

The nanoparticles were developed by company cofounders Ralph Weissleder, director of the Center for Molecular Imaging Research at Harvard, and Lee Josephson, associate professor of radiology at Harvard Medical School. Josephson says that the key advantage to T2 Biosystems’ diagnostic is that it doesn’t rely on optical signals. Traditional biochemical diagnostic techniques all require extensive sample processing because light doesn’t travel well through the body or through opaque liquids like blood, which must therefore be purified. The signal created by the magnetic nanoparticles does.

No preparation is necessary for T2 Biosystems’ tests. A sample is simply combined with the nanoparticles and put in the relaxometer to take a reading. (Relaxometers are commercially available and could be incorporated into hospital laboratories.)

Josephson expects the nanoparticle diagnostic to have a “very large advantage over the state of the art” in the area of infectious disease. He and Weissleder have used the nanoparticles to identify, among other pathogens, common viruses including herpes simplex and adenoviruses, as well as the bacteria that cause tuberculosis. Identifying the cause of a patient’s infection using traditional means, such as culturing bacteria, can require a great deal of time, says Josephson. Genomic techniques for identifying viruses and bacterial strains, such as PCR, also require sample preparation. The sooner the pathogen is identified, the sooner the patient can be given the right antibiotic or isolated and prevented from infecting other people. This is especially important in the case of a viral outbreak like SARS or influenza, or when a patient harboring drug-resistant bacteria enters a hospital.

2 comments. Share your thoughts »

Credit: Ralph Weissleder, Harvard Center for Molecular Imaging Research

Tagged: Business, MIT, nanotechnology, diagnostics, nanoparticles, MRI, virus, magnetics

Reprints and Permissions | Send feedback to the editor

From the Archives


Introducing MIT Technology Review Insider.

Already a Magazine subscriber?

You're automatically an Insider. It's easy to activate or upgrade your account.

Activate Your Account

Become an Insider

It's the new way to subscribe. Get even more of the tech news, research, and discoveries you crave.

Sign Up

Learn More

Find out why MIT Technology Review Insider is for you and explore your options.

Show Me